Avid Bioservices Inc (CDMO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Avid Bioservices Inc (CDMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12404
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Avid Bioservices Inc (Avid Bioservices), formerly Peregrine Pharmaceuticals Inc, is a biopharmaceutical company that develops, manufactures and markets monoclonal antibodies for the treatment and diagnosis of cancer. The company’s products include Bavituximab, PGN650 and Cotara. Its Bavituximab is a monoclonal antibody that binds to a basic component of the cell structure called a phospholipid. Avid Bioservices’s Cotara is in phase clinical development for the treatment of glioblastoma multiforme. The company utilizes technologies such as phosphatidylserine-targeting therapy for cancers and viral diseases and tumor necrosis therapy. It conducts clinical trials through collaboration with other oncology groups. Avid Bioservices is headquartered in Tustin, California, the US.

Avid Bioservices Inc (CDMO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Avid Bioservices Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Avid Bioservices Inc, Medical Devices Deals, 2012 to YTD 2018 10
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 12
Peregrine Pharma Expands its Agreement with AstraZeneca 13
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 14
Equity Offering 15
Peregrine Pharma to Raise USD30 Million in Public Offering of Shares 15
Peregrine Pharma to Raise USD12.3 Million in Public Offering of Shares 16
Peregrine Pharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Series E Preferred Stock For US$19.4 Million 17
Peregrine Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 19
Peregrine Pharma Completes Private Placement Of Shares For US$14 Million 20
Peregrine Pharma Files Registration Statement For Private Placement Of Common Stock For US$75 Million 21
Avid Bioservices Inc – Key Competitors 22
Avid Bioservices Inc – Key Employees 23
Avid Bioservices Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Strategy And Business Planning 25
Apr 24, 2018: Avid Bioservices Provides Update on Ongoing Expansion of Process Development Capabilities and Laboratory Infrastructure 25
Jul 31, 2017: Peregrine Provides Strategic Update 26
Financial Announcements 28
Dec 11, 2017: Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments 28
Sep 11, 2017: Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments 31
Jul 14, 2017: Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments 33
Mar 13, 2017: Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments 36
Corporate Communications 38
Dec 26, 2017: Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer 38
Oct 24, 2017: Peregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid Bioservices 39
Oct 19, 2017: Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices 40
Sep 11, 2017: Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices 41
Aug 11, 2017: Peregrine Announces Measures to Reduce Costs, Facilitate Profitability and Strengthen its Operations 42
Product News 43
May 01, 2017: MilliporeSigma’s Mobius 2,000-liter Single-use Bioreactors to Expand Avid Bioservices’ Manufacturing Capabilities 43
Other Significant Developments 44
Jan 05, 2018: Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO) 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Avid Bioservices Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Avid Bioservices Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Avid Bioservices Inc, Medical Devices Deals, 2012 to YTD 2018 10
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 12
Peregrine Pharma Expands its Agreement with AstraZeneca 13
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 14
Peregrine Pharma to Raise USD30 Million in Public Offering of Shares 15
Peregrine Pharma to Raise USD12.3 Million in Public Offering of Shares 16
Peregrine Pharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Series E Preferred Stock For US$19.4 Million 17
Peregrine Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 19
Peregrine Pharma Completes Private Placement Of Shares For US$14 Million 20
Peregrine Pharma Files Registration Statement For Private Placement Of Common Stock For US$75 Million 21
Avid Bioservices Inc, Key Competitors 22
Avid Bioservices Inc, Key Employees 23

List of Figures
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Avid Bioservices Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Avid Bioservices Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Avid Bioservices Inc (CDMO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Crescita Therapeutics Inc (CTX):企業の財務・戦略的SWOT分析
    Summary Crescita Therapeutics Inc (Crescita Therapeutics) operates as a commercial dermatology company that offers prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. The company’s products comprise Pliaglis, Alyria, Laboratoire Dr Renaud, Pro-De …
  • Kindred Healthcare, Inc.:戦略・SWOT・企業財務分析
    Kindred Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kindred Healthcare, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Centrais Eletricas de Santa Catarina SA (CLSC4):企業の財務・戦略的SWOT分析
    Centrais Eletricas de Santa Catarina SA (CLSC4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Chevron Corporation (CVX):石油・ガス:M&Aディール及び事業提携情報
    Summary Chevron Corp (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for, produces and transports crude oi …
  • Marui Group Co., Ltd.:企業の戦略・SWOT・財務情報
    Marui Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Marui Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Spherix Inc (SPEX):企業の財務・戦略的SWOT分析
    Spherix Inc (SPEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Sumitomo Mitsui Trust Holdings Inc
    Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Applied Materials Inc (AMAT):企業の財務・戦略的SWOT分析
    Applied Materials Inc (AMAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Network Rail Ltd:企業の戦略的SWOT分析
    Network Rail Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Daicel Corporation (4202):企業の財務・戦略的SWOT分析
    Daicel Corporation (4202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tuesday Morning Corporation (TUES):企業の財務・戦略的SWOT分析
    Tuesday Morning Corporation (TUES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Veristat LLC-製薬・医療分野:企業M&A・提携分析
    Summary Veristat LLC (Veristat), a subsidiary of Veristat Holding Inc is a clinical research organization that conducts clinical trials. The organization offers clinical monitoring, clinical project management, data management, CDISC implementation, biostatistics, medical writing, project management …
  • Gamuda Berhad:企業の戦略・SWOT・財務情報
    Gamuda Berhad - Strategy, SWOT and Corporate Finance Report Summary Gamuda Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Jet Airways (India) Ltd.:企業の戦略・SWOT・財務情報
    Jet Airways (India) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jet Airways (India) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Royal DSM N.V.:企業のM&A・事業提携・投資動向
    Royal DSM N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Royal DSM N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Microchip Technology Inc (MCHP):企業の財務・戦略的SWOT分析
    Microchip Technology Inc (MCHP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Hanwha Chemical Corp (009830):企業の財務・戦略的SWOT分析
    Summary Hanwha Chemical Corp (Hanwha), a subsidiary of Hanwha Corp is a chemical company that manufactures, develops, and distributes basic industrial chemicals, general purpose plastic products, and other chemical products. The company's chemical products include inorganic compounds, PVC, polymers, …
  • Cabot Energy Plc (CAB):石油・ガス:M&Aディール及び事業提携情報
    Summary Cabot Energy Plc (Cabot), formerly Northern Petroleum, is an independent upstream oil and gas company. It explores for, develops, and produces oil and natural gas; and trades assets. The company operates in onshore and offshore projects including gas producing fields and oil fields. Cabot's …
  • Twenty-First Century Fox Inc. (FOXA):企業の財務・戦略的SWOT分析
    Twenty-First Century Fox Inc. (FOXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Bourbon SA (GBB)-石油・ガス分野:企業M&A・提携分析
    Summary Bourbon SA (Bourbon) is a provider of marine and subsea services to the oil and gas industry. The company’s services consist of transport and supply of offshore material, floating production, storage and offloading (FPSO) support, anchor handling, towage and offshore positioning, assistance, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆